RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS

Regional Analysis

Recurrent Glioblastoma Multiforme Treatment Market – Regional Analysis

North America accounted for the largest share in the global recurrent glioblastoma multiforme treatment market in 2019, owing to the presence of major market players, increasing healthcare awareness, and FDA approvals for novel drugs in the market. For instance, in October 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients. Their DB102 treatment was approved for a study to gauge the efficacy in combination with temozolomide (Temodar) and radiation.

Moreover, the adoption of research & development and collaboration strategies by major players in the North America region are also contributing to growth of the global recurrent glioblastoma multiforme treatment market. For instance, in October 2019, UCLA and Advaxix entered into a research collaboration for glioblastoma multiforme (GBM) immunotherapy products. The aim of Advaxix behind this collaboration was to conduct preclinical studies assessing the Lm technology of UCLA in mouse tumor models of GBM.

Furthermore, Asia Pacific companies are also investing in R&D for novel treatment of GBM. Companies such as Samsung Bioepis, Kazia Therapeutics, and others are involved in research & development of novel drugs for the treatment of recurrent glioblastoma multiforme. For instance, in March 2018, the Australia-based Kazia Therapeutics, a biopharma company, started phase II clinical trials in the U.S. for its drug, GDC-0084. Moreover, a novel vaccine, Rindopepimut, is in last-stage development in Australia and India for first-line GBM treatment.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC, Israel, Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa